AbbVie Launches Scholarship to Support Students Living with Rheumatologic Diseases

- Scholarship to provide financial support for exceptional students living with rheumatologic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis or ankylosing spondylitis, as they pursue higher education goals

- Fifteen scholars to be awarded $15,000 each for 2016-2017 school year

- Scholarship now accepting applications; submission deadline is April 4, 2016

News provided by

AbbVie

Feb 11, 2016, 09:00 ET

NORTH CHICAGO, Ill., Feb. 11, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, announced the launch of the AbbVie Rheumatology Scholarship, designed to provide financial support for exceptional students living with a rheumatologic disease as they pursue higher education goals. Fifteen scholars will be selected to receive $15,000 each for the 2016-2017 school year. The AbbVie Rheumatology Scholarship is currently accepting applications.

"At AbbVie, we go beyond the medicine by using our resources to improve healthcare and communities," said Tracie Haas, vice president, corporate social responsibility, brand and communications, AbbVie. "By introducing the AbbVie Rheumatology Scholarship, we hope to support those living with rheumatologic diseases today so that they can prepare to succeed tomorrow."

In addition to the Rheumatology Scholarship, AbbVie also operates the AbbVie CF Scholarship, for students living with cystic fibrosis, which completed its 23rd year in 2015, and also launched the AbbVie Crohn's & Colitis Scholarship in December 2015 to support those living with inflammatory bowel disease.

About the AbbVie Rheumatology Scholarship
The scholarship is available to students living with rheumatologic disease, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis or ankylosing spondylitis, who are seeking a trade school diploma or an associate, undergraduate or graduate degree from an accredited U.S. trade school, college or university. Recipients will be chosen based on academic excellence, community involvement, written response to an essay question and ability to serve as a positive role model for the rheumatology community. The application period will close on April 4, 2016, 10 a.m. CT, and final notification to scholarship winners will be made by April 29, 2016.

It is not necessary for applicants to have taken, currently take or intend to take in the future any medicine or product marketed by AbbVie; this will not be a consideration in the recipient selection criteria.

For access to the online application, additional information about the application process and full eligibility details, please visit www.RheumScholarship.com.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

SOURCE AbbVie